Positive FDA feedback and an AUD 8 million capital raise have extended the cash runway through FY 2028, supporting key clinical milestones. Multiple programs are advancing, with pivotal trial starts and major data readouts expected by year-end.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.